Search PubMed⌕ Search

Biomedical subjects

G D Sweeney

Publications and source records attributed to G D Sweeney.

At least 37 records · Page 2Linked to original sources

Variability in the human drug response.

Variations in response to drugs may be pharmacodynamic, implying inter-individual differences in the response of receptors in equal concentrations of drug, or pharmacokinetic, implying that individuals receiving the same dose of drug will have different concentrations of drug in their body fluids. Either type of variation can be inherited or acquired. Variations in receptor sensitivity do occur but few instances, inherited or acquired, have well documented clinical relevance. If the dose response relationship for the drug in question is not steep, or if the therapeutic index is low, drug concentration in the region of the receptor will not be critical and causes of kinetic variation are unlikely to be clinically significant. However, it is the many causes of kinetic variation which are best described. These include effects due to drug formulation and changes in the absorption, distribution, metabolism and excretion of drugs. If a consideration of dynamics suggests that drug concentration will determine therapeutic efficacy, analysis and prediction of variability due to these factors is desirable. Prediction requires an accurate description of the system but commonly used pharmacokinetic models may fail when prediction is a goal. The variables, volume of distribution (Vd) and rate constant of elimination (Ke) are hybrid in that they arise from the interaction of patient and drug characteristics. Important events including macromolecular binding and altered blood flow may not be represented. More data is required to determine the clinical significance of pharmacodynamic variation but better analytical tools are required to deal with kinetic variation when this is important. Specifically, pharmacokinetic models should represent physiological variables and levels of unbound drug in body fluids should receive greater emphasis.

Biological Availability↗

Drugs--some basic concepts.

Increasing numbers of persons with heart, lung, kidney, musculoskeletal, and behavioral disorders who take medically prescribed drugs are choosing an active lifestyle. However, we know little about the effects of exercise on drug metabolism or how drugs might affect exercise performance. In this paper some basic concepts underlying pharmacokinetics (the study of determinants of drug concentration) and of pharmacodynamics (the study of the biological effects of drugs) will be considered. Although there is relatively little data related to exercise, an understanding of these pharmacological principles can be widely applied.

Absorption↗

Changes in rat hepatocyte plasma membranes caused by synthetic estrogens.

Livers of rats treated with ethynyl estradiol show hepatocyte swelling, nuclear enlargement, and an increase in size and numbers of nucleoli. Mitotic figures are frequent and there is occasional hepatocyte necrosis. Thin sections (1-micron. thick) show separation of cells with gaps between. Ultrastructurally, these gaps are occupied by cell membrane microville. These microvilli are not a normal feature on cell borders between adjacent hepatocytes. Similar anomalous microvilli are a feature of hepatocytes in regenerating nodules of cirrhosis, regenerating hepatocytes following partial hepatectomy, and in embryonic liver tissue. The significance of this finding and the known relationship of contraceptive agents and liver tumors is discussed.

Animals↗

Porphyria cutanea tarda: clinical and laboratory features.

Eleven patients with porphyria cutanea tarda were studied. Biochemical confirmation of the clinical diagnosis required only determination of the total urine porphyrin concentration in a sample of urine voided on rising in the morning. The patients were divided for convenience of discussion into four groups differing in age, sex and etiologic factors. Of the six patients in whom a liver biopsy was done one was shown to have micronodular cirrhosis. Except for a modest elevation in the serum glutamic oxaloacetic transaminase values when the patients were first seen, no evidence was found for liver disease apart from the presence of porphyria cutanea tarda. One patient recovered solely by abstaining from alcohol consumption. Five patients underwent phlebotomy; their iron stores had been found to be between 2 and 3 g. Decreasing urine porphyrin values correlated well with decreasing serum ferritin values during the course of phlebotomy. Porphyria cutanea tarda, which is due to a deficiency of uroporphyrinogen decarboxylase, is manifested in association with alcohol abuse, estrogen therapy, exposure to chlorinated hydrocarbons or increased tissue iron stores, or a combination of these factors. Although relatively uncommon, this condition raises important and unresolved issues regarding the hepatotoxicity of alcohol, estrogens, chlorinated hydrocarbons and iron.

Adult↗

Quantitation of urinary porphyrins by use of second-derivative spectroscopy.

We describe a simple, rapid procedure for measuring porphyrins in urine. After acidification of a urine specimen with hydrochloric acid, the second derivative of the absorption spectrum is recorded in the region of the Soret band maximum. The amplitude of the deflection is linearly related to porphyrin concentration, and the point at which the second derivative minimum occurs provides an estimate of the ratio of uroporphyrin to coproporphyrin in the sample. Nonspecific interference is not significant and reproducibility is excellent. Porphyrin excretion was studied in 24-h urine collections from men and non-pregnant as well as pregnant women. Median daily porphyrin excretion (nmol) was: men, 65.0; non-pregnant women, 60.1; and third-trimester pregnant women, 175.0. Distribution of these data was significantly skewed; upper and lower 2.5 percentile limits are given.

Female↗

Effects of phenobarbital and 3-methylcholanthrene pretreatment on size, sedimentation velocity, and mixed function oxygenase activity of rat hepatocytes.

SVA was used to separate liver cells from rats pretreated for 3 days with PB (40 mg/kg intraperitoneally, twice daily) or 3-MC (50 MG/KG AS A SINGLE INJECTIOn). Twelve fractions of cells were collected with s's ranging from 97 mm/hr (fraction1) to 25 mm/hr (fraction 12). Cells in each fraction were sized and counted electronically. PB caused the average volume of the largest cells recovered (fraction 1) to increase to 16, 725 micrometer3 from 10,500 micrometer3 previously reported in untreated animals. The number of cells recovered in the fast-sedimenting fractions (1 to 6) also increased, but there was only a small rise in the average model volume of hepatocytes determined prior to SVA. In cell suspensions analyzed after PB treatment no evidence was found for a discontinuity in the distribution of density-volume characteristics as previously described in hepatocytes from untreated rats. As expected, prior to sedimentation analysis, hepatocyte suspensions from rats treated with PB contained increased cytochrome P-450. The average ratio (n = 4) of P-450 in separated to unseparated cells ranged from 2.75 (fractions 1 + 2) to 0.38 (fractions 11 + 12), giving a 6.8-fold range in quantity of cytochrome per cell. Over this range, cell volume increased 4.2-fold, indicating a gradient in P-450 concentration similar to that previously reported to exist in cells from untreated rat liver. The gradient for AHH activity was 6.7-fold, suggesting that activity of MFO's paralleled the increase in cytochrome concentration. 3-MC pretreatment caused no significant increase in either size or number of cells in the fast-sedimenting fractions, but the discontinuity in density-volume characteristics which distinguished fast and slow sedimenting cells of untreated rats became marked. Furthermore, both the size and number of cells recovered in fractions 7 to 11 (which include the modal peal volume of unseparated hepatocytes) were increased. The gradient of P-450 (OR P1-450) was less steep in 3-MC-treated cells with pooled fractions 1 and 2 containing an average of 4.62 times as much cytochrome as fractions 11 and 12. The gradient for AHH was 4.29 times. The range of cell volume was 3.3-fold over this range. Additional experimental work was performed to determine whether P-450, AHH, or NADPH cytochrome c reductase exhibited differences in activity or concentration per unit of cell volume between cells on either side of fraction 7 where discontinuity had been noted. Each variable was expressed per unit of cell volume in fractions 5 and 9; ratios were compared but were indistinguishable from unity. It was concluded that induction of MFO activity had occurred equally in both populations of cells. Densities were calculated from s and cell volume. Noticeable loss of density followed PB treatment in cells of all sizes. 3-MC had less of an effect on density but enhanced the increment in density observed at fraction 7, which corresponds to the division between cells with distinct sedimentation characteristics...

Animals↗

Association between induction of aryl hydrocarbon hydroxylase and depression of uroporphyrinogen decarboxylase activity.

Mice that were genetically responsive (C57BL/6J) or non-responsive (DBA/2J) to induction of aryl hydrocarbon hydroxylase were treated with equal doses of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (25 microgram/kg/wk, i.p.) for five weeks. Urine porphyrin excretion remained unchanged in the non-responsive mice but was increased in the responsive group two weeks following the first dose and continued to rise. Upon sacrifice, uroporphyrinogen decarboxylase activity was found to be normal in the non-responsives but decreased 48% in the responsive mice. These results suggest a relationship between induction of aryl hydrocarbon hydroxylase and the decreased uroporphyrinogen decarboxylase activity resulting from exposure to chlorinated aromatic hydrocarbons.

Animals↗

Binding of anticonvulsant drugs to cytochrome P-450: correlation with evidence of induction of hepatic microsomal enzymes.

Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital. Diphenylhydantoin, phenobarbital, and pheneturide have previously been shown to enhance the urinary excretion of D-glucaric acid (DGA), while sulthiame inhibited the potentiation of DGA excretion caused by these drugs, and ethosuximide produced no change. The results suggest a close relationship between the ability of these drugs to induce hepatic microsomal drug-metabolizing enzyme systems (as indicated by enhancement of DGA excretion) and binding behaviour at the type 1 site.

Animals↗

A relative deficiency of cytochrome P-450 and aryl hydrocarbon [benzo(a)pyrene] hydroxylase in hyperplastic nodules induced by 2-acetylaminofluorene in rat liver.

The concentrations of cytochrome P-450 and the activities of aryl hydrocarbon [benzo(a)pyrene] hydroxylase (AHH) and reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase were measured in early (gray-white) and remodeled (brown) hyperplastic nodules induced in the livers of rats with 2-acetylaminofluorene and were compared to the values in control livers and in the liver surrounding the nodules. Cytochrome P-450 content of early (14 weeks) hyperplastic nodules is 30% of the activity of untreated control livers and 48% of the activity of the surrounding liver. AHH activity of the early nodules is 10% of the control activity and 33% of the activity in the surrounding nonnodular liver. Nicotinamide adenine dinucleotide phosphate-cytochrome c reductase activity in the microsomes of early nodules is 76% of the control activity and 78% of the activity in the surrounding liver. In the late remodeled nodules, (22 and 25 weeks), the cytochrome P-450 content is 40% of that of controls and AHH activity is 15% of the control activity. In primary hepatomas induced by 2-acetylaminofluorene, cytochrome P-450 content is 21% of that of controls, AHH activity is 11% of the activity of controls, and reductase is 50% of the control activity. These results, indicating a relative nodule deficiency in some of the cellular components believed to be important in the activation of hepatocarcinogens and hepatotoxins, offer one possible explanation for the relative resistance to carcinogen cytotoxicity of hyperplastic liver nodules.

2-Acetylaminofluorene↗